ClinicalTrials.gg
RecruitingNCT07361640DiaMesterUpdated Jan 23, 2026

DiaMester Pilot RCT: E-health Lifestyle Program for Type 2 Diabetes

An interventional study of e-health lifestyle program and Low calorie diet in Diabetes Mellitus, Type 2, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 116 studies in Diabetes Mellitus, Type 2 with a site in Norway — 3 open to participants now, 4 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Norway.

Planned enrollment
87th of 103
99 · median 503
Started
2026
the only one that year
No phase
24 of 116
2 open now
Registered
116th of 116
by date
Lead sponsor
4 of 116
Oslo University Hospital

Among the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, this one is the 87th largest by planned enrollment of the 103 interventional ones that give a count, is the only one that started in 2026, is one of 24 with no phase, and was the 116th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 116 studies in Diabetes Mellitus, Type 2 with a site in Norway are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Diabetes Mellitus, Type 2 with a site in Norway, or all of them as a file.
02

Study summary

This registration covers a pilot for a 3-armed parallel-group randomized controlled trial (RCT) that will evaluate the efficacy of DiaMester, a Norwegian e-health programme designed to improve self-management and induce clinically meaningful weight loss, and thereby potential remission in adults with type 2 diabetes (T2D).

Read the detailed description

The aim of this pilot RCT is to test the feasibility of the program and to investigate to what extent the program contributes to the intended improvement in lifestyle, self-management, metabolic risk factors and body weight. We also aim to investigate if participants in the e-health program achieve a clinically meaningful weight loss in each of the two intervention arms: one including a low-calorie diet (LCD) total diet replacement (TDR) induction phase and one without the use of a LCD.

The DiaMester app serves as a secure communication platform between each participant and an assigned health coach, who provides individually tailored advice on diet and physical activity and monitors progress towards agreed weight-loss targets. Six health coaches (clinical dietitians or diabetes nurses) will deliver the intervention, each having completed the same standardized training prior to study start.

Hypotheses:

Primary objective: To test whether participation in the DiaMester e-health program with an LCD induction phase results in greater weight loss compared to usual care after 12 months.

H1: The e-health + LCD group will achieve greater weight loss after 12 months than the control group

Secondary objectives:

A. To test whether participation in the DiaMester e-health program alone (without LCD) results in greater weight loss compared to usual care after 12 months.

H2: The e-health-only group will achieve greater weight loss than the control group after 12 months

B. Secondary outcomes include diet quality, lifestyle, physical activity, metabolic risk factors, and health related quality of life (HRQoL), self-management, eating disorder symptoms and diabetes distress. Both the LCD and no LCD intervention groups will be compared with the control group (usual care).

We hypothesize that compared to usual care, the e-health program supported lifestyle interventions will H3: Improve diet quality (in line with dietary recommendations), lifestyle index score and increase participants' physical activity H4: Improve the metabolic risk factors HbA1c, blood lipids, and blood pressure, H5: Reduce the use of blood glucose/lipid lowering drugs and/or blood pressure lowering drugs H5: Increase HRQoL and self-management and lower the level of diabetes distress.

H6: Not increase eating disorder symptoms

C: To examine possible mediating and moderating factors for the effect on body weight and metabolic risk factors H6: The intervention's effect on bodyweight is mediated by change in diet quality and physical activity H7: The intervention's effect on HbA1c, blood lipids and blood pressure is mediated by change in bodyweight, diet quality and physical activity H8: The effect of weight loss on HbA1c is moderated by diabetes duration, BMI and age

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • diabetes
  • diabetes mellitus type 2
  • e-health
  • self-management
  • weight loss
  • low calorie diet
  • remission induction
  • total diet replacement
  • caloric restriction
  • diet therapy
  • health psychology
  • eating disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Men and women aged ≥ 18 years
  • Type 2 diabetes of duration 0-6 years (diagnosis based on 2 recorded diagnostic-level tests, and/or blood glucose)
  • HbA1c ≥ 48 mmol/mol at the last routine clinical check, within last 12 months if on diet alone
  • HbA1c ≥ 43 mmol/mol if on treatment with oral hypoglycaemic agents or GLP-1 RA treatment
  • (BMI) >27 kg/m2
  • Stable body weight during the last 6 months with or without the use of weight-reducing drugs
  • Self-reported desire to lose weight
  • Owns a smartphone

Exclusion criteria

Exclusion criteria:

  • Current insulin use
  • > 5% weight change or started treatment with weight reducing drugs* within the last 6 months. *orlistat (Xenical), bupropion-naltrekson (Mysimba), fenteramin-topiramat (Qsimba), semaglutid (Wegovy, Ozempic), tirzepatid (Mounjaro), liraglutid (Saxenda, Victoza), dulaglutid (Truicity).
  • Recent routine ≥108 mmol/mol
  • Recent \<30 ml/min/1.73 m\^2
  • Known cancer
  • Myocardial infarction within previous 6 months
  • Severe heart failure defined as equivalent to the grade 3 (NYHA)
  • Pregnancy/considering pregnancy or exclusively breastfeeding
  • Substance abuse (drugs, alcohol)
  • Diagnosed eating disorders or suspected ED based on screening questionnaire
  • Learning difficulties or unable to understand, speak and read Norwegian or English
  • Patients who have required hospitalization for depression or are on antipsychotic drugs
  • People currently participating in another clinical research trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    1

    E-health program with LCD

    Behavioral: e-health lifestyle program · Behavioral: Low calorie diet

  • Experimental
    2

    E-health program without LCD

    Behavioral: e-health lifestyle program

  • No intervention
    3

    Standard care, but with continuous glucose monitoring (CGM) for 10 days at baseline and 1 year.

Interventions

  • Behaviorale-health lifestyle program

    The e-health lifestyle program consists of three parts: 1. an educational digital course module that can be tailored to the users' individual needs and preferences. This will include videos and interactive webinars accessible through the program, hosted by health specialists with users as guests. 2. individual and group-based digital lifestyle coaching by trained health care personnel through secure video-conference and chat solutions. 3. a mobile-phone-based self-management app. This app will offer the user relevant data and information from glucometer and smart watch according to the users' needs and preferences as well as easy ways for recording dietary intake, physical activity and other relevant parameters.

    Also known as: Lifestyle intervention, e-health based intervention, m-health intervention, digital behavioural intervention, weight loss intervention, total diet replacement low caloric diet

  • BehavioralLow calorie diet

    Participants will use a low calorie diet (LCD) total diet replacement (TDR) for the first 3 months of the 1 year intervention period, before gradual reintroduction of food.

06

What researchers measure

Primary outcomes

  1. Change in body weight from baseline (weight loss)

    Body weight (kg) will be measured by the participants' GPs. Change in body weight will be reported as percentage weight loss and will be analysed as a continuous variable.

    Time frame: Body weight will be assessed at baseline, 3 months, 6 months, 9 months and 12 months.

Secondary outcomes

  1. Change in HbA1c from baseline

    HbA1c (mmol/mol) will be measured by the participants GPs and will be analysed as a continuous variable.

    Time frame: HbA1c will be measured at baseline, 3 months, 6 months, 9 months and 12 months.

  2. Change in blood lipids from baseline

    Lipids (mmol/L) (total cholesterol, low density cholesterol, high density cholesterol, triglycerides, non-high density cholesterol) will be measured by the participants GPs and will be analysed as a continuous variable.

    Time frame: Lipids will be measured at baseline, 6 months and 12 months

  3. Change in blood pressure from baseline

    Change in blood pressure (mmHg) will be measured by the participants GPs and will be analysed as a continuous variable.

    Time frame: Blood pressure will be measured at baseline, 3 months, 6 months, 9 months and 12 months.

  4. Change in blood glucose time in range from baseline

    Average blood glucose will be collected form continuous glucose monitors (CGM).

    Time frame: Participants' in the control group will wear a CGM for 10 days at baseline and 1 year, while participants' in the two intervention groups will wear a CGM for 40 days at baseline, 40 days at 6 months and 10 days at one year.

  5. Change in average blood glucose baseline

    Average blood glucose will be collected form continuous glucose monitors (CGM).

    Time frame: Participants' in the control group will wear a CGM for 10 days at baseline and 1 year, while participants' in the two intervention groups will wear a CGM for 40 days at baseline, 40 days at 6 months and 10 days at one year.

  6. Change in use of medications from baseline

    Type of blood glucose lowering drugs, lipid lowering drugs and blood pressure lowering drugs. We will report how many participants that are using zero, one and more than one glucose lowering drug, lipid lowering drug and blood pressure lowering drug. In addition, we will report the number of participants that are using GLP-1 analogues.

    Time frame: Use of medications will be assessed at baseline, 3 months, 6 months, 9 months and 12 months.

  7. Change in diet quality from baseline

    Data on diet quality will be collected using 24 hour recall for 3 separate days at each time point. The Norwegian Diet Index (1) will be adapted to create a new index reflecting the Norwegian dietary guidelines for diabetes and the European recommendations for the dietary management of diabetes (The Diabetes and Nutrition Study Group of the EASD 2023). In addition, intake of nutrients and key food groups will be evaluated.

    Time frame: Diet quality will be assessed at baseline, 6 months and 1 year.

  8. Change in physical activity from baseline

    Physical activity will be scored on the short form of the International physical activity questionnaire (IPAQ-SF) (2). For participants in the intervention groups physical activity (energy expenditure and steps) will be recorded with smart watches.

    Time frame: Physical activity will be assessed at baseline and 1 year follow up.

  9. Change in health related quality (HRQoL) of life from baseline

    HRQoL will be measured using the EQ-5D-5L (3).

    Time frame: Measured at baseline and 1 year follow-up

  10. Change in diabetes distress of life from baseline

    Diabetes distress will be measured using the problem Areas in Diabetes Scale (PAID) (4) and/or the Diabetes Distress Scale (DDS) (5). Time frame: Measured at baseline and 1 year follow-up

    Time frame: Measured at baseline and 1 year follow-up

  11. Change in diabetes self-management from baseline

    Diabetes self-management will be measured using the problem Diabetes Empowerment Scale-Short Form (DES-SF) (6).

    Time frame: Measured at baseline and 1 year follow-up

  12. Change in eating disorder symptoms from baseline

    Eating disorder symptoms will be measured using the Eating Disorder Examination Questionnaire (EDE-Q) (7, 8). Individuals with a score indicating high likelihood of ED at baseline will undergo an interview evaluating diagnostic criteria.

    Time frame: Measured at baseline and 1 year follow-up

  13. Prevalence of likely eating disorder at baseline

    Eating disorder symptoms will be measured using the problem EDE-Q. Individuals with a score indicating high likelihood of ED at baseline will undergo an interview evaluating diagnostic criteria.

    Time frame: Measured at baseline

07

Study locations

1 of 1 sites recruiting
  • Oslo University Hospital
    Oslo, 0424, Norway
    Recruiting
    • Anne-Marie Aas, Phd · Contacta.m.aas@medisin.uio.no · +47 47302912
    • Lise M Østli, MSc · Contactl.m.ostli@medisin.uio.no · +47 97180196
    • Kåre I Birkeland, PhD · Sub investigator
    • Line Wisting, PhD · Sub investigator
    • Kirsti Bjerkan, MSc · Sub investigator
    • Monica H Carlsen, PhD · Sub investigator
    • Milada Hagen, PhD · Sub investigator
    • Eirik Årsand, PhD · Sub investigator
    • Tina Rishaug, MSc · Sub investigator
08

References and documents

Publications

  • Fairburn CG, Beglin SJ. Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord. 1994 Dec;16(4):363-70. PubMed 7866415 ↗
  • Anderson RM, Fitzgerald JT, Gruppen LD, Funnell MM, Oh MS. The Diabetes Empowerment Scale-Short Form (DES-SF). Diabetes Care. 2003 May;26(5):1641-2. doi: 10.2337/diacare.26.5.1641-a. No abstract available. PubMed 12716841 ↗
  • Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, Jackson RA. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005 Mar;28(3):626-31. doi: 10.2337/diacare.28.3.626. PubMed 15735199 ↗
  • Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, Schwartz CE. Assessment of diabetes-related distress. Diabetes Care. 1995 Jun;18(6):754-60. doi: 10.2337/diacare.18.6.754. PubMed 7555499 ↗
  • Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727-36. doi: 10.1007/s11136-011-9903-x. Epub 2011 Apr 9. PubMed 21479777 ↗
  • Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB. PubMed 12900694 ↗
  • Henriksen HB, Berg HB, Andersen LF, Weedon-Fekjaer H, Blomhoff R. Development of the Norwegian diet index and the Norwegian lifestyle index and evaluation in a national survey. Food Nutr Res. 2023 Sep 29;67. doi: 10.29219/fnr.v67.9217. eCollection 2023. PubMed 37808205 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared, as participants have not consented to data sharing beyond the purposes of the present study, and the data contain sensitive health information protected under GDPR.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Sep 2027, 20 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 20 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 23, 2026
StartEst.
Jan 14, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07361640
Collaborators
University of Tromso, Abel Technologies AS, The Dam Foundation, Diabetes Wellness Norway, Norwegian Diabetes Association, University of Oslo
Responsible party
Anne-Marie Aas (Associate Professor and Clinical Dietitian, Oslo University Hospital) — Principal investigator
First posted
Jan 23, 2026
Start date
Jan 14, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Anne-Marie Aas, PhD
Contact
a.m.aas@medisin.uio.no
+47 47302912
Lise M Østli, MSc
Contact
l.m.ostli@medisin.uio.no
+47 97180196
Anne-Marie Aas, PhD
principal investigator · Oslo University Hospital and University of Oslo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion